Lansoprazole crystal compound

Abstract

The invention relates to the field of anti-ulcer medicines, and in particular relates to a lansoprazole crystal compound. The character of the lansoprazole crystal compound is crystal; the chemical name of the lansoprazole crystal compound is 2-[[[3-methyl-4-(2,2,2-trifluoroethoxyl)-2-pyridyl] methyl] sulfinyl]-1H-benzimidazole, namely C16H14F3N3O2S; according to a mass spectrum, the molecule ion peak of the product is [M+H]<+>; and the mass-to-charge ratio m / z is 370. The preparation method comprises the following steps of: performing a condensation reaction and an oxidation reaction, and then performing refining. According to the lansoprazole crystal compound, proper raw materials are adopted, and the cost is low; the crystal compound has extremely good treating effects for ulcer diseases such as gastric ulcer, duodenal ulcer, refractory ulcer, reflux esophagitis and pancreatic original ulcer after being taken properly; an experiment shows that the lansoprazole crystal compound is basically non-toxic, can treat the ulcer in a more quick and effective manner and is low in recurrence rate; through repeated experimental selection, the defined preparation method is simple and feasible; the selected raw materials are readily available; and the cost is low.

Description

technical field

[0001] The invention relates to the field of anti-ulcer drugs, in particular to a crystal compound of lansoprazole. Background technique

[0002] Ulcerative disease is a common type of disease, and it is prone to recurrent clinically, often accompanied by serious complications, such as gastric and duodenal ulcers, which may be complicated by upper gastrointestinal bleeding and perforation, which seriously threaten people's health. Proton pump inhibitors are powerful weapons in the fight against ulcer disease.

[0003] Lansoprazole (Lansoprazole) is the second proton pump inhibitor anti-ulcer drug in the world developed by Takeda after Omeprazole (Omeprazole). This product is a new type of drug that inhibits gastric acid secretion, it acts on the H of gastric parietal cells ＋ -K ＋ -ATPase. H ＋ It cannot be transported to the stomach, so that the amount of gastric acid in the gastric juice is greatly reduced. It is clinically used for duodenal ulcer, gastr...

Images